BrainStorm Reports Q2 Loss, $0.2M Cash; Prepares Phase 3b ALS Trial
BCLI has more than doubled off its 52-week low of $0.459 on elevated volume (2.5× avg).
Summary
BrainStorm Cell Therapeutics reported Q2 2026 results with a $3.9M net loss and only $0.2M in cash, while advancing its Phase 3b ALS trial under an FDA SPA.
Key Events · Earnings and Guidance · BCLI
-
Q2 Net Loss of $3.9M
Net loss for Q2 2026 was $3.9 million, compared to $2.9 million in Q2 2025. Loss per share was $(0.35).
-
Cash Drops to $0.2M
Cash, cash equivalents, and restricted cash totaled approximately $0.2 million as of June 30, 2026, down from $1.03 million a year earlier.
-
Phase 3b ENDURANCE Trial Readiness
Company is completing operational and regulatory work to open the Phase 3b ENDURANCE trial for NurOwn in ALS, conducted under an FDA Special Protocol Assessment.
-
Executive Chairman Appointment
Peter J. Pitts, former FDA Associate Commissioner, was appointed Executive Chairman in July 2026 to lead regulatory and capital-markets initiatives.
Analysis · BCLI · Life Sciences
BrainStorm Cell Therapeutics reported a Q2 net loss of $3.9 million with only $0.2 million in cash as of June 30, 2026, down from $1.03 million a year earlier. The company is advancing the Phase 3b ENDURANCE trial for NurOwn in ALS under an FDA Special Protocol Assessment, but the cash position raises urgent questions about its ability to fund operations through trial initiation. The appointment of Peter Pitts as Executive Chairman adds regulatory expertise, but the financial runway is critically short.
At the time of this filing, BCLI was trading at $0.99 on OTC in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.46 to $1.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.